Dr Freedland on the FDA Approval of Enzalutamide in nmCSPC :

Stephen J. Freedland, MD, discusses the significance of the FDA approval of enzalutamide in nonmetastatic castration-sensitive prostate cancer.

Related Keywords

Stephenj Freedland , , Research In Cancer , Prevention Program , Department Of Urology , Samuel Oschin Comprehensive Cancer Institute , Warschaw Robertson Law Families Chair , Prostate Cancer , Integrated Research , Cancer Genetics , Cedars Sinai , Nonmetastatic Castration Sensitive Prostate Cancer , Enzalutamide , Embark ,